Blome James Form 4 Calyxt / James Blome ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Blome James

(Last) (First) (Middle)

2800 MOUNT RIDGE ROAD

(Street)

ROSEVILLE MN 55113

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Calyxt, Inc. [ CLXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/28/2019

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/28/2019		A		50,000(1)	A	$0	204,136	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right-to-Buy)	$12.48	06/28/2019		A		125,000		06/28/2020(2)	06/28/2029	Common Stock	125,000	$0	125,000	D
Performance Stock Units	(3)	06/28/2019		A		166,667		(3)	06/28/2022	Common Stock	166,667	$0	166,667	D

Explanation of Responses:

1. 50,000 Restricted Stock Units with respect to Calyxt, Inc. common stock were granted to reporting person on 6/28/2019 and vest as to 15% of the underlying shares on the first anniversary of the Grant Date, as to 10% of the underlying shares on the second anniversary of the Grant Date, and as to 5% of the underlying shares on the last day of each calendar quarter beginning on the first full calendar quarter after the second anniversary of the Grant Date.

2. Stock Option vests as to 15% of the underlying shares on the first anniversary of the Grant Date, as to 10% of the underlying shares on the second anniversary of the Grant Date, and as to 5% of the underlying shares on the last day of each calendar quarter beginning the first full calendar quarter after the second anniversary of the Grant Date.

3. Each performance stock unit (PSU) represents a contingent right to receive one share of Calyxt common stock. The PSU will vest as to 50%, 100% or 120% of the shares at the end of a three year performance period based upon increases in Calyxt common stock from the starting price of $12.48 (and on a linear basis between vesting percentages) and if vested, will be issued as restricted stock with restrictions lapsing on the two year anniversary of the date of issuance.

	Dr. Andre Choulika, Attorney-in-Fact for James Blome	07/02/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.